[Ip-health] KEI supplemental submission to USTR Special 301 review

Elizabeth Rajasingh elizabeth.rajasingh at keionline.org
Mon Mar 2 09:24:11 PST 2015


In response to questions posed during the Special 301 Hearing on February
24, 2015, KEI provided the office of the USTR with comments on R&D, online
pharmacies, and the relationship between health emergencies and compulsory
licensing.

The complete comments can be found on KEI's website:

KEI's Feb 27, 2015 Supplemental Comments to USTR Regarding Research and
Development.
http://keionline.org/node/2185

KEI's supplemental comments in USTR 301: Online pharmacies, parallel trade
and counterfeit drugs.
http://keionline.org/node/2186  <http://keionline.org/node/2186>

KEI Special 301 supplemental comments: Compulsory Licensing not restricted
to "Emergencies" or "Measure of Last Resort".
http://keionline.org/node/2187

A complete look at KEI's work with the special 301 review can be found on
our webpage: http://keionline.org/ustr/special301
<http://keionline.org/ustr/special301>

All of the comments and replies submitted to the USTR can be found at:
http://www.regulations.gov/#!documentDetail;D=USTR-2014-0025-0001


----
Elizabeth Rajasingh
Perls Research and Policy Fellow, Knowledge Ecology International
1621 Connecticut Ave. NW, Suite 500
Washington, DC 20009
*elizabeth.rajasingh at keionline.org <elizabeth.rajasingh at keionline.org>* |
 1-202-332-2670



More information about the Ip-health mailing list